193 related articles for article (PubMed ID: 23292974)
1. Romiplostim resistance in secondary failure of platelet recovery.
DeRemer DL; Katsanevas K; Bradley A; Awan FT
J Oncol Pharm Pract; 2013 Dec; 19(4):369-72. PubMed ID: 23292974
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of romiplostim for the treatment of secondary failure of platelet recovery among allogeneic hematopoietic stem cell transplant patients.
Hartranft ME; Clemmons AB; DeRemer DL; Kota V
J Oncol Pharm Pract; 2017 Jan; 23(1):10-17. PubMed ID: 26471738
[TBL] [Abstract][Full Text] [Related]
3. Romiplostim for chronic lymphocytic leukemia-associated immune thrombocytopenia.
D'Arena G; Cascavilla N
Leuk Lymphoma; 2011 Apr; 52(4):701-4. PubMed ID: 21171868
[No Abstract] [Full Text] [Related]
4. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study.
Newland A; Godeau B; Priego V; Viallard JF; López Fernández MF; Orejudos A; Eisen M
Br J Haematol; 2016 Jan; 172(2):262-73. PubMed ID: 26537623
[TBL] [Abstract][Full Text] [Related]
5. Romiplostim for the management of perioperative thrombocytopenia.
Al-Samkari H; Marshall AL; Goodarzi K; Kuter DJ
Br J Haematol; 2018 Jul; 182(1):106-113. PubMed ID: 29767837
[TBL] [Abstract][Full Text] [Related]
6. Persistent thrombocytopenia post auto-SCT for AML treated with romiplostim in a patient with HIV.
Gangatharan SA; Cooney JP
Bone Marrow Transplant; 2011 Sep; 46(9):1280-1. PubMed ID: 21151181
[No Abstract] [Full Text] [Related]
7. Use of romiplostim in a hemodialysis patient with primary immune thrombocytopenia.
Al-Jafar H; Giagounidis A; El-Rashaid K; Al-Ali M; Hakim AA
Ann Pharmacother; 2012 Nov; 46(11):e31. PubMed ID: 23115229
[TBL] [Abstract][Full Text] [Related]
8. Thrombopoietin receptor agonists can be used temporarily with patients suffering from refractory chronic lymphocytic leukemia-associated immunologic thrombocytopenia.
Sinisalo M; Sankelo M; Itälä-Remes M
Leuk Lymphoma; 2011 Apr; 52(4):724-5. PubMed ID: 21323511
[No Abstract] [Full Text] [Related]
9. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
[TBL] [Abstract][Full Text] [Related]
10. Romiplostim efficacy in an acute myeloid leukemia patient with transfusion refractory thrombocytopenia.
Berthelot-Richer M; Boilard B; Morin A; Bolduc B; Beauregard P; Kotb R
Transfusion; 2012 Apr; 52(4):739-41. PubMed ID: 22082044
[TBL] [Abstract][Full Text] [Related]
11. Response of complex immune-mediated thrombocytopenia to romiplostim in the setting of allogeneic stem cell transplantation for chronic myelogenous leukemia.
Bollag RJ; Sterett M; Reding MT; Key NS; Cohn CS; Ustun C
Eur J Haematol; 2012 Oct; 89(4):361-4. PubMed ID: 22775392
[No Abstract] [Full Text] [Related]
12. Romiplostim.
Kuter DJ
Cancer Treat Res; 2011; 157():267-88. PubMed ID: 21052962
[TBL] [Abstract][Full Text] [Related]
13. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study.
Tarantino MD; Bussel JB; Blanchette VS; Despotovic J; Bennett C; Raj A; Williams B; Beam D; Morales J; Rose MJ; Carpenter N; Nie K; Eisen M
Lancet; 2016 Jul; 388(10039):45-54. PubMed ID: 27103127
[TBL] [Abstract][Full Text] [Related]
14. Treatment of 5 dogs with immune-mediated thrombocytopenia using Romiplostim.
Kohn B; Bal G; Chirek A; Rehbein S; Salama A
BMC Vet Res; 2016 Jun; 12():96. PubMed ID: 27283401
[TBL] [Abstract][Full Text] [Related]
15. [Progression of bone marrow fibrosis with reticulin and collagen hyperplasia during treatment with the thrombopoietin receptor agonist romiplostim in a patient with immune thrombocytopenia].
Kirito K; Komatsu N
Rinsho Ketsueki; 2013 Mar; 54(3):295-9. PubMed ID: 23676646
[TBL] [Abstract][Full Text] [Related]
16. Immune thrombocytopenia and anticoagulation: the role of romiplostim in the early treatment.
Cantoni N; Heizmann M; Bargetzi M
Br J Haematol; 2012 Jun; 157(5):639-41. PubMed ID: 22329466
[No Abstract] [Full Text] [Related]
17. Increased requirement for platelet transfusions concurrent with enhanced bleeding during romiplostim treatment in a patient with thrombocytopenia due to bone marrow failure.
Lotfi R; Moeller P; Schmid M; Schrezenmeier H
Ann Hematol; 2011 Nov; 90(11):1357-9. PubMed ID: 21327404
[No Abstract] [Full Text] [Related]
18. Romiplostim for thrombocytopenia following allogeneic stem cell transplantation: A case series.
Lancman G; Coltoff A; Steinberg A
Hematol Oncol Stem Cell Ther; 2020 Sep; 13(3):171-174. PubMed ID: 30030975
[TBL] [Abstract][Full Text] [Related]
19. Successful antiviral therapy for hepatitis C virus-induced cirrhosis after an increase in the platelet count with romiplostim: two case reports.
Voican CS; Naveau S; Perlemuter G
Eur J Gastroenterol Hepatol; 2012 Dec; 24(12):1455-8. PubMed ID: 22890208
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia.
Kantarjian H; Fenaux P; Sekeres MA; Becker PS; Boruchov A; Bowen D; Hellstrom-Lindberg E; Larson RA; Lyons RM; Muus P; Shammo J; Siegel R; Hu K; Franklin J; Berger DP
J Clin Oncol; 2010 Jan; 28(3):437-44. PubMed ID: 20008626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
